drugset / Trial / NCT01407276

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

NCT01407276

Phase 1 Completed 49 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3 mg dose by mouth.

Timeline

Start
2011-08-08
Primary completion
2012-03-23
Completion
2012-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Omarigliptin Small molecule 3 mg Oral